Literature DB >> 16688228

Prognostic value of cyclin D2 mRNA expression in newly diagnosed multiple myeloma treated with high-dose chemotherapy and tandem autologous stem cell transplantations.

I Hanamura, Y Huang, F Zhan, B Barlogie, J Shaughnessy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16688228     DOI： 10.1038/sj.leu.2404253

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  28 in total

1.  MUC1-C drives MYC in multiple myeloma.

Authors:  Ashujit Tagde; Hasan Rajabi; Audrey Bouillez; Maroof Alam; Reddy Gali; Shannon Bailey; Yu-Tzu Tai; Teru Hideshima; Kenneth Anderson; David Avigan; Donald Kufe
Journal:  Blood       Date:  2016-02-23       Impact factor: 22.113

2.  Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma.

Authors:  Tiziana Bruno; Francesca De Nicola; Giacomo Corleone; Valeria Catena; Frauke Goeman; Matteo Pallocca; Cristina Sorino; Gianluca Bossi; Bruno Amadio; Giovanni Cigliana; Maria Rosaria Ricciardi; Maria Teresa Petrucci; Enrico Pierluigi Spugnini; Alfonso Baldi; Mario Cioce; Giancarlo Cortese; Elisabetta Mattei; Roberta Merola; Umberto Gianelli; Luca Baldini; Francesco Pisani; Svitlana Gumenyuk; Andrea Mengarelli; Katja Höpker; Thomas Benzing; Bruno Vincenzi; Aristide Floridi; Claudio Passananti; Giovanni Blandino; Simona Iezzi; Maurizio Fanciulli
Journal:  Blood Adv       Date:  2020-11-24

3.  Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).

Authors:  Rashid Khan; Madhav Dhodapkar; Adam Rosenthal; Christoph Heuck; Xenofon Papanikolaou; Pingping Qu; Frits van Rhee; Maurizio Zangari; Yogesh Jethava; Joshua Epstein; Shmuel Yaccoby; Antje Hoering; John Crowley; Nathan Petty; Clyde Bailey; Gareth Morgan; Bart Barlogie
Journal:  Haematologica       Date:  2015-05-28       Impact factor: 9.941

4.  MUC1-C is a target in lenalidomide resistant multiple myeloma.

Authors:  Li Yin; Ashujit Tagde; Reddy Gali; Yu-Tzu Tai; Teru Hideshima; Kenneth Anderson; David Avigan; Donald Kufe
Journal:  Br J Haematol       Date:  2017-06-23       Impact factor: 6.998

5.  IQGAP1 Scaffold-MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal.

Authors:  Christian B Gocke; Ross McMillan; Qiuju Wang; Asma Begum; Vesselin R Penchev; Syed A Ali; Ivan Borrello; Carol Ann Huff; William Matsui
Journal:  Mol Cancer Ther       Date:  2016-08-29       Impact factor: 6.261

6.  Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma.

Authors:  Scott Van Wier; Esteban Braggio; Angela Baker; Gregory Ahmann; Joan Levy; John D Carpten; Rafael Fonseca
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

Review 7.  The molecular characterization and clinical management of multiple myeloma in the post-genome era.

Authors:  Y Zhou; B Barlogie; J D Shaughnessy
Journal:  Leukemia       Date:  2009-08-06       Impact factor: 11.528

8.  Pyk2 promotes tumor progression in multiple myeloma.

Authors:  Yu Zhang; Michele Moschetta; Daisy Huynh; Yu-Tzu Tai; Yong Zhang; Wenjing Zhang; Yuji Mishima; Jennifer E Ring; Winnie F Tam; Qunli Xu; Patricia Maiso; Michaela Reagan; Ilyas Sahin; Antonio Sacco; Salomon Manier; Yosra Aljawai; Siobhan Glavey; Nikhil C Munshi; Kenneth C Anderson; Jonathan Pachter; Aldo M Roccaro; Irene M Ghobrial
Journal:  Blood       Date:  2014-09-12       Impact factor: 22.113

9.  NOTCH is part of the transcriptional network regulating cell growth and survival in mouse plasmacytomas.

Authors:  Dong-Mi Shin; Daniel J Shaffer; Hongsheng Wang; Derry C Roopenian; Herbert C Morse
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

10.  High expression of chaperonin-containing TCP1 subunit 3 may induce dismal prognosis in multiple myeloma.

Authors:  Tingting Qian; Longzhen Cui; Yan Liu; Zhiheng Cheng; Liang Quan; Tiansheng Zeng; Wenhui Huang; Yifeng Dai; Jinghong Chen; Ling Liu; Jingqi Chen; Ying Pang; Guangsheng Wu; Xu Ye; Jinlong Shi; Lin Fu; Chaozeng Si
Journal:  Pharmacogenomics J       Date:  2020-01-06       Impact factor: 3.550
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.